A detailed history of Campbell & CO Investment Adviser LLC transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Campbell & CO Investment Adviser LLC holds 43,541 shares of CPRX stock, worth $907,394. This represents 0.06% of its overall portfolio holdings.

Number of Shares
43,541
Previous 95,079 54.21%
Holding current value
$907,394
Previous $2.31 Million 59.05%
% of portfolio
0.06%
Previous 0.18%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Aug 07, 2025

SELL
$21.4 - $26.31 $1.1 Million - $1.36 Million
-51,538 Reduced 54.21%
43,541 $944,000
Q1 2025

May 14, 2025

BUY
$19.53 - $25.74 $1.86 Million - $2.45 Million
95,079 New
95,079 $2.31 Million
Q1 2024

May 10, 2024

BUY
$13.18 - $17.11 $253,082 - $328,546
19,202 New
19,202 $306,000
Q1 2023

May 11, 2023

SELL
$14.34 - $21.05 $404,215 - $593,357
-28,188 Reduced 47.05%
31,721 $525,000
Q4 2022

Feb 14, 2023

SELL
$12.25 - $19.5 $154,999 - $246,733
-12,653 Reduced 17.44%
59,909 $1.11 Million
Q3 2022

Nov 14, 2022

SELL
$7.06 - $15.52 $577,543 - $1.27 Million
-81,805 Reduced 52.99%
72,562 $931,000
Q2 2022

Aug 09, 2022

BUY
$6.23 - $8.57 $118,282 - $162,710
18,986 Added 14.02%
154,367 $1.08 Million
Q1 2022

May 09, 2022

BUY
$5.31 - $8.31 $314,251 - $491,794
59,181 Added 77.67%
135,381 $1.12 Million
Q4 2021

Feb 10, 2022

BUY
$5.21 - $7.45 $231,845 - $331,525
44,500 Added 140.38%
76,200 $516,000
Q3 2021

Nov 10, 2021

SELL
$4.85 - $6.04 $54,319 - $67,648
-11,200 Reduced 26.11%
31,700 $168,000
Q2 2021

Aug 11, 2021

BUY
$4.29 - $6.05 $184,041 - $259,545
42,900 New
42,900 $247,000

Others Institutions Holding CPRX

About CATALYST PHARMACEUTICALS, INC.


  • Ticker CPRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 102,820,000
  • Market Cap $2.14B
  • Description
  • Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...
More about CPRX
Track This Portfolio

Track Campbell & CO Investment Adviser LLC Portfolio

Follow Campbell & CO Investment Adviser LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Campbell & CO Investment Adviser LLC, based on Form 13F filings with the SEC.

News

Stay updated on Campbell & CO Investment Adviser LLC with notifications on news.